all report title image

HIV-ASSOCIATED LIPODYSTROPHY TREATMENT MARKET ANALYSIS

HIV-Associated Lipodystrophy Treatment Market, by Lipodystrophy Type (Lipoatrophy and Lipoaccumulation), by Therapeutic class (Anabolism Modulators, Insulin Resistance Modulators, Mitochondrial Antioxidants (l-carnitine), and Other), by Distribution Channels (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) and by Geography - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2022-2028

  • To Be Published : Dec 2024
  • Code : CMI1269
  • Formats :
      Excel and PDF
  • Industry : Pharmaceutical

HIV-Associated Lipodystrophy Treatment MarketSize and Trends

Increasing prevalence of HIV is expected to drive growth of the HIV-associated lipodystrophy treatment market

According to an article published in Journal of AIDS & Clinical Research in 2014, prevalence of lipodystrophy in patients suffering from HIV varies significantly and was estimated between 32.4% and 88.6%. According to World Health Organization (WHO) in 2017, more than 35 million people are suffering from HIV worldwide and an estimated 1.0 million people died from HIV in 2016. Increasing prevalence of HIV is expected to drive growth of the HIV-associated lipodystrophy market as most (32.4-88.6%) of the people suffering from HIV also suffer from HIV-associated lipodystrophy.

Approval of novel drugs in key regions such as North America is expected to drive the growth of HIV-Associated Lipodystrophy Market. For instance, in 2014, Theratechnologies Inc. received approval from Health Canada for its EGRIFTA. It is a growth hormone-releasing factor (GRF) for the treatment of HIV-associated lipodystrophy. EGRIFTA had also received the U.S. Food and Drug Administration (FDA) approval in 2010. Such approval of new drugs in the key region is expected to drive growth of the HIV-associated lipodystrophy treatment market.

The global HIV-associated lipodystrophy treatment market is segmented on the basis of lipodystrophy type, therapeutic class, and distribution channel.

On the basis of lipodystrophy type, the global HIV-associated lipodystrophy treatment market is segmented into:

  • Lipoatrophy
  • Lipoaccumulation

On the basis of therapeutic class, the global HIV-associated lipodystrophy treatment market is segmented into:

  • Anabolism modulators
  • Growth hormones
  • Anabolic steroids
  • Insulin resistance modulators
  • Metformins
  • Thiazolidinediones
  • Others
  • Mitochondrial antioxidants (l-carnitine)
  • Other miscellaneous metabolic agents

On the basis of the distribution channel, the global HIV-associated lipodystrophy treatment market is segmented into:

  • Hospital pharmacies
  • Retail pharmacies
  • Online pharmacies

Market- Trends

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Customize Now
Logo

Credibility and Certifications

ESOMAR
DUNS Registered
Clutch
DMCA Protected

9001:2015

Credibility and Certifications

27001:2022

Credibility and Certifications

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo
© 2024 Coherent Market Insights Pvt Ltd. All Rights Reserved.